Showing 5901-5910 of 21466 results for "".
- Early-Life Stress: A Risk Factor for Developing Psoriasishttps://reachmd.com/news/early-life-stress-a-risk-factor-for-developing-psoriasis/2484258/According to a Swedish birth‑cohort analysis, changes in family structure during infancy were associated with an al
- Enhancing Diagnosis of Adenoviral Conjunctivitis: Silver-Amplified Lateral Flow Kits in Focushttps://reachmd.com/news/enhancing-diagnosis-of-adenoviral-conjunctivitis-silver-amplified-lateral-flow-kits-in-focus/2484248/A recent multicenter prospective study in Viruses shows that silver‑amplified lateral flow kits substantially improve point‑of‑care detection of adenoviral conjunctivitis, with sensitivity 86.0
- Tapinarof Sustains AD Remission for 75+ Days Post-Treatmenthttps://reachmd.com/news/tapinarof-sustains-ad-remission-for-75-days-post-treatment/2484253/New long-term data from the ADORING 3 trial show that tapinarof cream 1% (VTAMA, Organon), a non-steroidal topical aryl hydrocarbon receptor agonist, can sustain low disease activity and pruritus in patients with atopic dermatitis (AD), including children as young
- Topical Caffeine May Provide Hair Growth Benefit for Alopecia: Studyhttps://reachmd.com/news/topical-caffeine-may-provide-hair-growth-benefit-for-alopecia-study/2484243/Topical caffeine may be a promising adjunct treatment for hair loss, according to a systematic review published in the Journal of Drugs in Dermatology. The analysis assessed original studies investigating caffeine’s effects on hair growth across multiple fo
- Advancing Neurodegenerative Diagnostics: The Role of TDP-43 PET Tracer ACI-19626https://reachmd.com/news/advancing-neurodegenerative-diagnostics-the-role-of-tdp-43-pet-tracer-aci-19626/2484108/AC Immune has introduced ACI-19626, a first-in-class TDP-43 PET tracer that could change diagnosis and trial design by enabling in vivo imaging of aggregated TDP‑43 in neurodegenerative disease. The company reports preclinical characterization published alongside a N
- Early-Life Stress: A Risk Factor for Developing Psoriasishttps://reachmd.com/news/early-life-stress-a-risk-factor-for-developing-psoriasis/2484234/A Swedish birth‑cohort analysis found that changes in family structure during infancy were associated with an almost threefold increase in later‑life psoriasis. Th
- Glucose Metabolism as a Key Driver in Metabolic-Related Liver Diseaseshttps://reachmd.com/news/glucose-metabolism-as-a-key-driver-in-metabolic-related-liver-diseases/2484228/An NHANES analysis finds glycemic markers—fasting glucose, HbA1c and insulin-resistance indices—track more closely with hepatic steatosis and liver s
- Advancements and Challenges in Ultrasound AI for Ovarian Tumor Detectionhttps://reachmd.com/news/advancements-and-challenges-in-ultrasound-ai-for-ovarian-tumor-detection/2484111/A multicenter retrospective study shows that combining a ResNet-50 visual model with LLM-generated descriptions improves static-ultrasound classification of ovarian tumors, boosting class-specific accuracy and narrowing sonographer variability, according to
- TrUE-AD4: Opzelura Shows Rapid, Significant Efficacy in Moderate ADhttps://reachmd.com/news/true-ad4-opzelura-shows-rapid-significant-efficacy-in-moderate-ad/2484225/New data from Incyte’s phase 3b TRuE-AD4 trial show that Opzelura® (ruxolitinib cream 1.5%) improved clinical symptoms of moderate atopic dermatitis (AD) in adults with limited response or intolerance to standard thearpy. The
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://reachmd.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture